{"id":868,"date":"2025-03-03T22:26:18","date_gmt":"2025-03-03T22:26:18","guid":{"rendered":"https:\/\/www.neurenati.com\/?post_type=news&#038;p=868"},"modified":"2025-03-10T22:26:35","modified_gmt":"2025-03-10T22:26:35","slug":"the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease","status":"publish","type":"news","link":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/","title":{"rendered":"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease"},"parent":0,"template":"","class_list":["post-868","news","type-news","status-publish","hentry"],"acf":{"post_link":"https:\/\/www.businesswire.com\/news\/home\/20250304216736\/en\/The-US-FDA-Grants-Both-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-to-NEU-001-of-Neurenati-for-the-Treatment-of-Hirschsprung-Disease"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Neurenati\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T22:26:35+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\\\/\",\"url\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\\\/\",\"name\":\"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/#website\"},\"datePublished\":\"2025-03-03T22:26:18+00:00\",\"dateModified\":\"2025-03-10T22:26:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/\",\"name\":\"Neurenati\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neurenati.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/","og_locale":"en_US","og_type":"article","og_title":"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati","og_url":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/","og_site_name":"Neurenati","article_modified_time":"2025-03-10T22:26:35+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/","url":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/","name":"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease - Neurenati","isPartOf":{"@id":"https:\/\/www.neurenati.com\/en\/#website"},"datePublished":"2025-03-03T22:26:18+00:00","dateModified":"2025-03-10T22:26:35+00:00","breadcrumb":{"@id":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.neurenati.com\/en\/news\/the-us-fda-grants-both-orphan-drug-and-rare-pediatric-disease-designations-to-neu-001-of-neurenati-for-the-treatment-of-hirschsprung-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.neurenati.com\/en\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/www.neurenati.com\/en\/news\/"},{"@type":"ListItem","position":3,"name":"The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.neurenati.com\/en\/#website","url":"https:\/\/www.neurenati.com\/en\/","name":"Neurenati","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neurenati.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.neurenati.com\/en\/wp-json\/wp\/v2\/neurenati-news\/868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neurenati.com\/en\/wp-json\/wp\/v2\/neurenati-news"}],"about":[{"href":"https:\/\/www.neurenati.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.neurenati.com\/en\/wp-json\/wp\/v2\/media?parent=868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}